DND Pharm Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
00:56
Jun 17
Jun 17
Contrarian biotech play against rate consensus
The market has overwhelmingly priced in higher interest rates, but oil prices may stay elevated and rate hikes may not be as severe. This creates a contrarian opportunity in beaten-down Korean biotech stocks. Year-end outlook for biotech and cosmetics is constructive, and it is time to start accumulating names like Alteogen, ABL Bio, LigaChem Bio, Sam Chun Dang Pharm, and DND Pharm rather than chasing momentum elsewhere.
MED
About DND Pharm Investor Commentary
Across the available history and selected sources, Buzzberg tracks DND Pharm across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Jang Woo-jin.